The
report "Radioimmunoassay
Market by Type
(Reagents & Kits, Analyzers), End User (Hospital, Pharmaceutical Industry,
Academics, Clinical Diagnostic Labs), Application (Research, Clinical
Diagnostics), and Geography - Global Forecast to 2020",
The global radioimmunoassay (RIA) market was valued at $345.2 Million in 2014
and is expected to reach $428.4 Million by 2020, at a CAGR of 3.5% during the
forecast period from 2015 to 2020.
Browse 75 market
data Tables and 68 Figures spread through 113 Pages and in-depth TOC on "Radioimmunoassay Market "
http://www.marketsandmarkets.com/Market-Reports/radioimmunoassay-market-172815697.html
http://www.marketsandmarkets.com/Market-Reports/radioimmunoassay-market-172815697.html
Early buyers
will receive 10% customization on This report.
Radioimmunoassay (RIA) is an in-vitro assay technique that is used
to measure the concentration of antigens in blood. RIA encompasses the
separation of protein from a mixture by using the specificity of antibody-
antigen binding and their quantitation by using radioactivity. The method is
hypersensitive and can quantify tiny amounts of hormone or drug level with the
help of antibodies.
Radioimmunoassay is used owing to its high sensitivity, which can
analyze nanomolar and picomolar concentrations of hormones in biological
fluids. RIA has become one of the major tools in various clinical laboratories
for diagnostic procedures, such as assessing the plasma levels of most of the
hormones, identifying the presence of certain abused drugs, evaluating the
presence of hepatitis B surface antigen in donated blood, and others. This
technique is also used for the early detection of cancer, treatment of peptic
ulcers, research with neurotransmitters, detection of infections, and
identification of allergens in food and house dust, and so on.
The increasing usage of RIA in pharmaceutical industries, research
labs, and contract research organizations (CROs) has led to an increased demand
of products that are based on this technique. Furthermore, the rising need for
quality and error-free results to ensure patient satisfaction has resulted in
research labs and diagnostic centers to opt for high-throughput and automated
procedures. This is also one of the major factors that have resulted in the
growth of the RIA market to a large extent.
There are two types of radioimmunoassay, which serve different
functions for clinical diagnostics and research purposes. These types have been
classified into reagents & kits and analyzers. In 2014, the reagents &
kits segment contributed the largest share of 82.9% to the global
radioimmunoassay market.
The various application areas of RIA are infectious disease
testing, endocrine testing, allergy testing, oncology testing, toxicology
testing, and autoimmune disease testing. Out of all the application segments,
oncology testing is the largest application segment, and is expected to hold
the major market share in the near future.
Based on this market’s end users, the global radioimmunoassay
market has been segmented into hospitals (hospital-based
laboratories/hospital-attached laboratories), academics, pharmaceutical
industry and CROs, clinical laboratories, and others, which include physician
offices, patient self-testing centers, blood banks, home health agencies,
nursing homes, and ambulatory surgical centers.
The Sample Report For This Report@
The global radioimmunoassay market has been categorized into major
geographical regions, including Europe, North America, Asia, and the Rest of
the world. Europe is the most dominant region in the global radioimmunoassay
market, and contributed a share of 35.1% in 2014; the market in this region was
valued at $121.5 Million in the same year.
Some of the major players in the radioimmunoassay globally are
DIAsource ImmunoAssays SA (Belgium), Beckman Coulter, Inc. (U.S.), IBL
International (A Tecan Company) (Germany), PerkinElmer, Inc. (U.S.), DRG
International, Inc. (U.S.), MP Biomedicals, LLC (U.S.), Cisbio (France), Euro
Diagnostica AB (Sweden), DiaSorin S.p.A.. (Italy), EMD Millipore (U.S.), Izotop
(Hungary), Berthold Technologies GmbH & Co. KG (Germany), Stratec
Biomedical AG (Germany), and others.
Get The PDF Brochure For This Report@
About MarketsandMarkets™:
MarketsandMarkets™
provides quantified B2B research on 30,000 high growth niche
opportunities/threats which will impact 70% to 80% of worldwide companies’
revenues. Currently servicing 5000 customers worldwide including 80% of global
Fortune 1000 companies as clients. Almost 75,000 top officers across eight
industries worldwide approach MarketsandMarkets™ for their painpoints around
revenues decisions.
Our 850
fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth
markets following the "Growth Engagement Model – GEM". The GEM aims
at proactive collaboration with the clients to identify new opportunities, identify
most important customers, write "Attack, avoid and defend"
strategies, identify sources of incremental revenues for both the company and
its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants
(Positioning top players across leaders, emerging companies, innovators,
strategic players) annually in high growth emerging segments.
MarketsandMarkets™ is determined to benefit more than 10,000 companies this
year for their revenue planning and help them take their innovations/disruptions
early to the market by providing them research ahead of the curve.
MarketsandMarkets’s
flagship competitive intelligence and market research platform, "RT"
connects over 200,000 markets and entire value chains for deeper understanding
of the unmet insights along with market sizing and forecasts of niche
markets.
Contact:
Mr. Rohan
MarketsandMarkets™
701
Pike Street
Suite
2175, Seattle,
WA
98101, United States
Tel:
1-888-600-6441
No comments:
Post a Comment